AWM Investment Company Inc. Sells 5,000 Shares of Repligen Co. (NASDAQ:RGEN)

AWM Investment Company Inc. cut its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 7.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 65,000 shares of the biotechnology company's stock after selling 5,000 shares during the quarter. AWM Investment Company Inc. owned approximately 0.12% of Repligen worth $9,356,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Signaturefd LLC increased its position in shares of Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 124 shares during the last quarter. Sava Infond d.o.o. bought a new position in shares of Repligen during the 4th quarter valued at about $29,000. Raiffeisen Bank International AG bought a new position in shares of Repligen during the 4th quarter valued at about $29,000. Itau Unibanco Holding S.A. bought a new position in shares of Repligen during the 4th quarter valued at about $40,000. Finally, UMB Bank n.a. increased its position in shares of Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 110 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on RGEN shares. Royal Bank of Canada dropped their target price on Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a report on Wednesday, April 30th. TD Cowen started coverage on Repligen in a report on Monday, February 10th. They set a "buy" rating and a $200.00 target price for the company. Canaccord Genuity Group dropped their target price on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a report on Wednesday, April 16th. HC Wainwright restated a "buy" rating and set a $180.00 target price on shares of Repligen in a report on Monday, May 5th. Finally, Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price for the company in a report on Tuesday, April 29th. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, Repligen has an average rating of "Moderate Buy" and an average target price of $173.25.

Repligen Trading Down 1.9%

NASDAQ RGEN traded down $2.30 on Friday, hitting $118.15. The company's stock had a trading volume of 615,767 shares, compared to its average volume of 739,361. Repligen Co. has a 52-week low of $102.97 and a 52-week high of $182.52. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The company's 50-day simple moving average is $130.28 and its 200 day simple moving average is $144.49. The firm has a market cap of $6.64 billion, a P/E ratio of -231.67, a PEG ratio of 4.54 and a beta of 1.21.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. During the same quarter last year, the business posted $0.28 EPS. The business's revenue was up 10.4% on a year-over-year basis. Research analysts predict that Repligen Co. will post 1.72 EPS for the current fiscal year.

Insiders Place Their Bets

In other Repligen news, Director Margaret Pax acquired 250 shares of the company's stock in a transaction on Monday, March 17th. The stock was acquired at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now owns 1,043 shares in the company, valued at $157,169.67. This represents a 31.53% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 1.20% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.